Navigation Links
Cannabis Science Announces The Depository Trust Company (DTC) Lifts Share Trading "Chill" Effective Immediately
Date:9/6/2013

COLORADO SPRINGS, Colo., Sept. 6, 2013 /PRNewswire/ -- Cannabis Science, Inc. (NASD OTC: CBIS), is proud to announce that the Depository Trust Company (DTC) has confirmed through official communication to the Company, effective immediately, it has lifted the deposit transaction restriction "Chill" and has resumed accepting and processing deposits.

Excerpt from the official DTC Letter to the Company,  "This letter is in response to your recent inquiries and submission regarding the deposit transaction restriction (the "Deposit Chill") on CUSIP 137648101 (the "Issue"), issued by Cannabis Science, Inc.

Please be advised that The Depository Trust Company has determined to lift the Deposit Chill and has resumed accepting deposits of the issue depository and book-entry transfer services."

Chad S. Johnson, Esq., Chief Operating Officer & General Counsel of Cannabis Science, stated, "This is great news and we are excited that the "Chill" has been removed.  Our entire team, especially our legal and accounting teams, worked diligently on this matter, and we are thankful for the work they have done."

Cannabis Science continues with its efforts working toward novel cannabis and cannabinoid-based drug development to treat certain infectious and age-related illnesses and skin cancers, including HIV related cancers like Kaposi's Sarcoma.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The medicinal use of cannabis has an extensive history dating back thousands of years, and currently there is a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illnesses. Our initial focus is on skin and other cancers including HIV related cancers such as Kaposi's Sarcoma.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934.  A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Colorado Springs, Colorado

Dr. Dorothy Bray, CEO & Director
Dr. Robert Melamede, President & Director
Chad S. Johnson, COO, General Counsel & Director
Mario Lap, President of European Operations & Director
info@cannabisscience.com

For Investor Inquires:

Robert Kane
Vice President of Investor Relations
rkane@cannabisscience.com
+1.561.420.4824


'/>"/>
SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
2. X-Change Corporation Signs Multi-Million Dollar Agreement for Multi-State Product Release Licensing, Medical Cannabis Dispensary Management, and Cultivation Consulting
3. American Drug War II: Cannabis Destiny is IMDBs Highest Rated 2013 Documentary
4. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
5. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
6. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
7. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
8. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
9. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
10. New Study Shows Cannabis Effects on Driving Skills
11. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):